The Lancet Gastroenterology & Hepatology· Nurulamin M Noor, Mohmmed Tauseef Sharip, Haiyan Zheng, Barry Widmer, Biljana Brezina, Kamal V Patel, Francis Dowling, Suhaylah Bhatti, Nadia Alsmade, Tariq Ahmad, Paul J Banim, James W Berrill, Rachel Cooney, Juan De La Revilla Negro, Shanika de Silva, Shahida Din, Dharmaraj Durai, John N Gordon, Ailsa L Hart, Peter M Irving, Matthew Johnson, Alexandra J Kent, Klaartje B Kok, Gordon W Moran, Craig Mowat, Pritash Patel, Tim Raine, Rebecca Saich, Dan Sharpstone, Melissa A Smith, Alan Steel, Sreedhar Subramanian, Alan Wiles, Horace R T Williams, James O Lindsay, Nicholas A Kennedy, Eoin F McKinney, Paul A Lyons, Kenneth G C Smith, James C Lee, David S Robertson, Miles Parkes, PROFILE Study Group·· 2026-09-11AI 评分55
PROFILE试验5年随访:新诊断克罗恩病早期top-down抗TNF治疗与step-up策略的长期结局对比
[Articles] Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial
AI 导读
PROFILE试验5年随访结果显示,新诊断的成人克罗恩病患者在确诊时即开始top-down抗TNF治疗,与常规step-up策略相比,5年长期结局改善相关。研究团队认为,这一结果提示早期top-down治疗可能具有疾病修饰作用。
来源:The Lancet Gastroenterology & Hepatology · thelancet.com